医学
强直性脊柱炎
双氯芬酸
随机对照试验
外科
射线照相术
临床终点
内科学
按需
麻醉
计算机科学
多媒体
作者
Joachim Sieper,Joachim Listing,Denis Poddubnyy,In‐Ho Song,K.-G. Hermann,Johanna Callhoff,Uta Syrbe,Jürgen Braun,Martín Rudwaleit
标识
DOI:10.1136/annrheumdis-2015-207897
摘要
Background
To date, only a single controlled trial provided evidence that non-steroidal anti-inflammatory drugs (NSAIDs) given continuously reduce radiographic progression compared with an on-demand therapy over 2 years in patients with ankylosing spondylitis (AS). In the current study, we tested whether such an effect of NSAIDs could be confirmed in another randomised trial. Methods
Patients with AS were randomised for treatment with either continuous (150 mg/day) or on-demand diclofenac for 2 years. Tumour necrosis factor-blocker treatment was not allowed during the entire study period. The primary outcome was the difference in radiographic progression in the spine as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) scored by two readers blinded to treatment arm and time point. Results
62 of 85 patients enrolled in the continuous arm and 60 of 82 enrolled in the on-demand arm completed the study. The mSASSS progression was numerically higher in the continuous group (1.28 (0.7 to 1.9) vs 0.79 (0.2 to 1.4)) (p=0.39). If only patients were analysed who were either C reactive protein positive or had syndesmophytes at baseline, there was again a higher radiographic progression in the continuous versus the on-demand group: 1.68 (0.7 to 2.6) vs 0.96 (0.0 to 1.9) and 2.11 (1.1 to 3.1) vs 0.95 (0.0 to 1.9), respectively. There was no difference between the two treatment groups regarding adverse events. Conclusions
In our study, continuous treatment with diclofenac over 2 years did not reduce radiographic progression compared with on-demand treatment in AS. Trial registration numbers
EudraCt-no 2007-007637-39; ClinicalTrials.gov NCT00715091.
科研通智能强力驱动
Strongly Powered by AbleSci AI